Brief History of Important Immunologic Discoveries and Developments
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Strokovno Poročilo UKCL 2019
STROKOVNO POROČILO 2019 STROKOVNO POROČILO 2019 Univerzitetni klinični center Ljubljana, Zaloška cesta 2, 1000 Ljubljana Odgovorna oseba: prof. dr. Jadranka Buturović Ponikar, dr. med., strokovna direktorica UKC Ljubljana Besedila za poročilo so prispevali: prof. dr. Zlatko Fras, mag. Jana Brguljan Hitij, prof. dr. Aleš Blinc, prof. dr. Matjaž Šinkovec, prof. dr. Marko Noč, prof. dr. Marjeta Terčelj, prof. dr. Borut Štabuc, prof. dr. Miha Arnol, doc. dr. Andrej Janež, prof. dr. Samo Zver, prof. dr. Matija Tomšič, Gregor Veninšek, doc. dr. Miran Brvar, dr. Hugon Možina, prof. dr. Matjaž Veselko, dr. Nikola Lakić, prof. dr. Roman Bošnjak, prof. dr. Uroš Ahčan, prof. dr. Matej Cimerman, prof. dr. Aleš Tomažič, dr. Tomaž Štupnik, asist. Bojan Štrus, prof. dr. Andrej Kansky, prof. dr. Vesna Novak Jankovič, doc. dr. Igor Frangež, prof. dr. Simon Podnar, prof. dr. Uroš Rot, doc., prof. dr. Adolf Lukanovič, doc. dr. Borut Kobal, Mag. Gorazd Kavšek, prof. dr. Eda Vrtačnik Bokal, Leon Meglič, prof. dr. Borut Peterlin, doc.dr. Marko Pokorn, doc. dr. Anamarija Meglič, prim. Mojca Brecelj Kobe, prof. dr.Tadej Avčin, Uroš Krivec, prof. dr. Rok Orel, prof. dr. Tadej Battellino, prof. dr. Tanja Kersnik Levart, prof. dr. Janez Jazbec, prof. dr. Darja Paro Panjan, prof. dr. David Neubauer, mag. Mojca Tomažič, asist. dr. Veronika Velenšek, prof. dr. Milan Petelin, prof. dr. Martina Drevenšek, dr. Rok Kosem, doc.dr. Milan Kuhar, doc. dr. Tatjana Lejko Zupanc, prof. dr. Mojca Globočnik Petrović, prof. dr. Vane Antolič, doc. dr. Aleksandar Aničin, prim. asist. Tanja Planinšek Ručigaj, doc.dr.. Dimitrij Kuhelj, doc. dr. Katja Zaletel, prof. dr. Milan Skitek, prof. -
Newsletteralumni News of the Newyork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010
NEWSLETTERAlumni News of the NewYork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010 CUMC 2007-2009 Transplant Activity Profile* Activity Kidney Liver Heart Lung Pancreas Baseline list at year start 694 274 174 136 24 Deceased donor transplant 123 124 93 57 11 Living donor transplant 138 17 — 0 — Transplant rate from list 33% 50% 51% 57% 35% Mortality rate while on list 9% 9% 9% 15% 0% New listings 411 217 144 68 23 Wait list at year finish 735 305 204 53 36 2007-June 2008 Percent 1-Year Survival No % No % No % No % No % Adult grafts 610 91 279 86 169 84 123 89 6 100 Adult patients 517 96 262 88 159 84 116 91 5 100 Pediatric grafts 13 100 38 86 51 91 3 100 0 — Pediatric patients 11 100 34 97 47 90 2 100 0 — Summary Data Total 2009 living donor transplants 155 (89% Kidney) Total 2009 deceased donor transplants 408 (30% Kidney, 30% Liver) 2007-June 2008 adult 1-year patient survival range 84% Heart to 100% Pancreas 2007-June 2008 pediatric 1-year patient survival range 90% Heart to 100% Kidney or lung *Health Resource and Service Administration’s Scientific Registry of Transplant Recipients (SRTR) Ed Note. The figure shows the US waiting list for whole organs which will only be partially fulfilled by some 8,000 deceased donors, along with 6,600 living donors, who will provide 28,000 to 29,000 organs in 2010. The Medical Center’s role in this process is summarized in the table, and the articles that follow my note expand on this incredible short fall and its potential solutions. -
Immune Effector Mechanisms and Designer Vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA
EXPERT REVIEW OF VACCINES https://doi.org/10.1080/14760584.2019.1674144 REVIEW How vaccines work: immune effector mechanisms and designer vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Three major advances have led to increase in length and quality of human life: Received 6 June 2019 increased food production, improved sanitation and induction of specific adaptive immune Accepted 25 September 2019 responses to infectious agents (vaccination). Which has had the most impact is subject to debate. KEYWORDS The number and variety of infections agents and the mechanisms that they have evolved to allow Vaccines; immune effector them to colonize humans remained mysterious and confusing until the last 50 years. Since then mechanisms; toxin science has developed complex and largely successful ways to immunize against many of these neutralization; receptor infections. blockade; anaphylactic Areas covered: Six specific immune defense mechanisms have been identified. neutralization, cytolytic, reactions; antibody- immune complex, anaphylactic, T-cytotoxicity, and delayed hypersensitivity. The role of each of these mediated cytolysis; immune immune effector mechanisms in immune responses induced by vaccination against specific infectious complex reactions; T-cell- mediated cytotoxicity; agents is the subject of this review. delayed hypersensitivity Expertopinion: In the past development of specific vaccines for infections agents was largely by trial and error. With an understanding of the natural history of an infection and the effective immune response to it, one can select the method of vaccination that will elicit the appropriate immune effector mechanisms (designer vaccines). These may act to prevent infection (prevention) or eliminate an established on ongoing infection (therapeutic). -
Medical Bacteriology
LECTURE NOTES Degree and Diploma Programs For Environmental Health Students Medical Bacteriology Abilo Tadesse, Meseret Alem University of Gondar In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education September 2006 Funded under USAID Cooperative Agreement No. 663-A-00-00-0358-00. Produced in collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education. Important Guidelines for Printing and Photocopying Limited permission is granted free of charge to print or photocopy all pages of this publication for educational, not-for-profit use by health care workers, students or faculty. All copies must retain all author credits and copyright notices included in the original document. Under no circumstances is it permissible to sell or distribute on a commercial basis, or to claim authorship of, copies of material reproduced from this publication. ©2006 by Abilo Tadesse, Meseret Alem All rights reserved. Except as expressly provided above, no part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission of the author or authors. This material is intended for educational use only by practicing health care workers or students and faculty in a health care field. PREFACE Text book on Medical Bacteriology for Medical Laboratory Technology students are not available as need, so this lecture note will alleviate the acute shortage of text books and reference materials on medical bacteriology. -
Transplanted Thymus Thymus Nor the Development of Impairs Neither the Recovery of Recipient Depleted Lymphocyte Infusion
CD4+ T Cell −Depleted Lymphocyte Infusion Impairs Neither the Recovery of Recipient Thymus nor the Development of Transplanted Thymus This information is current as of September 26, 2021. Ming Shi, Ming Li, Yunze Cui, Lin Liu, Yasushi Adachi and Susumu Ikehara J Immunol 2013; 190:2976-2983; Prepublished online 4 February 2013; doi: 10.4049/jimmunol.1201605 Downloaded from http://www.jimmunol.org/content/190/6/2976 Supplementary http://www.jimmunol.org/content/suppl/2013/02/04/jimmunol.120160 http://www.jimmunol.org/ Material 5.DC1 References This article cites 36 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/190/6/2976.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD4+ T Cell–Depleted Lymphocyte Infusion Impairs Neither the Recovery of Recipient Thymus nor the Development of Transplanted Thymus Ming Shi,* Ming Li,* Yunze Cui,*,† Lin Liu,* Yasushi Adachi,*,‡ and Susumu Ikehara* Thymus transplantation, in conjunction with bone marrow transplantation (BMT), has been attracting attention for the treatment of various diseases. -
Thymus Transplantation Reference Number: CP.MP.189 Coding Implications Date of Last Revision: 06/21 Revision Log
Clinical Policy: Thymus Transplantation Reference Number: CP.MP.189 Coding Implications Date of Last Revision: 06/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Complete DiGeorge anomaly is a disorder in which a person has no thymus function. Without thymus function, bone marrow stem cells do not develop into T cells, which results in immunodeficiency. Without successful treatment, patients usually die by 2 years of age. Thymus transplantation with and without immunosuppression has resulted in the development good T cell function in complete DiGeorge anomaly subjects.1 Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that thymus transplant (use of RVT-802) requires secondary review, due to limited evidence, when meeting all of the following: A. Complete or “atypical” DiGeorge syndrome with poor thymus function, per medical testing laboratory studies and physical examination, as confirmed by the thymus transplant clinical trial (NCT01220531); B. Immunodeficiency, or severe autoimmunity for which development of naïve T cells would be expected to lead to clinical improvement; C. Flow cytometry and phytohaemagglutinin (PHA) studies are planned to occur twice, once within 3 months of transplantation and once within one month of transplantation. Studies must be performed in a CLIA or CAP certified laboratory, preferably Duke Clinical Immunology Laboratory; D. None of the following contraindications: 1. Malignancy, except for non-melanoma localized skin cancer that has been treated appropriately, a malignancy that has been completely resected, or a treated malignancy determined to have a small likelihood of recurrence and acceptable future risks; 2. -
Thymocytes May Persist and Differentiate Without Any Input from Bone Marrow Progenitors
Brief Definitive Report Thymocytes may persist and differentiate without any input from bone marrow progenitors Laetitia Peaudecerf,1 Sara Lemos,1 Alessia Galgano,1 Gerald Krenn,1 Florence Vasseur,1 James P. Di Santo,2 Sophie Ezine,1 and Benedita Rocha1 1Institut National de la Santé et de la Recherche Médicale, Unit 1020, Faculty of Medicine Descartes Paris V, 75015 Paris, France 2Innate Immunity Unit, Pasteur Institute, 75724 Paris, France Thymus transplants can correct deficiencies of the thymus epithelium caused by the com- plete DiGeorge syndrome or FOXN1 mutations. However, thymus transplants were never used to correct T cell–intrinsic deficiencies because it is generally believed that thymocytes have short intrinsic lifespans. This notion is based on thymus transplantation experiments where it was shown that thymus-resident cells were rapidly replaced by progenitors origi- nating in the bone marrow. In contrast, here we show that neonatal thymi transplanted into interleukin 7 receptor–deficient hosts harbor populations with extensive capacity to self-renew, and maintain continuous thymocyte generation and export. These thymus transplants reconstitute the full diversity of peripheral T cell repertoires one month after surgery, which is the earliest time point studied. Moreover, transplantation experiments performed across major histocompatibility barriers show that allogeneic transplanted thymi are not rejected, and allogeneic cells do not induce graft-versus-host disease; transplants induced partial or total protection to infection. These results challenge the current dogma that thymocytes cannot self-renew, and indicate a potential use of neonatal thymus trans- plants to correct T cell–intrinsic deficiencies. Finally, as found with mature T cells, they show that thymocyte survival is determined by the competition between incoming progeni- tors and resident cells. -
Module 2: Diphtheria
The Immunological Basis for Immunization Series Module 2: Diphtheria DEPARTMENT OF VACCINES AND BIOLOGICALS ~-) World Health Organization ~ ~ fJ! Geneva ----~ WHO/EPI/GEN/93.12 ORIGINAL: ENGLISH DISTR.: GENERAL The Immunological Basis for Immunization Series Module 2: Diphtheria Dr Artur M. Galazka Medical Officer Expanded Programme on Immunization DEPARTMENT OF VACCINES AND BIOLOGICALS .) World Health Organization ~ , ~ ~ Geneva ~ I iJff 2001 ~~ The Department of Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible. United Nations Development Fund (UNDP) The Rockefeller Foundation The Government of Sweden The Immunological Basis for Immunization series is available in English and French (from the address below). It has also been translated by national health authorities into a number of other languages for local use: Chinese, Italian, Persian, Russian, Turkish, Ukranian and Vietnamese. The series comprises eight independent modules: Module 1: General immunology Module 2: Diphtheria Module 3: Tetanus Module 4: Pertussis Module 5: Tuberculosis Module 6: Poliomyelitis Module 7: Measles Module 8: Yellow fever Produced in 1993 Reprinted (with new covers but no changes to content) in 2001 Ordering code: WHO/EPI/GEN/93.12 This document is available on the Internet at: www.who.int/vaccines-documents/ Copies may be requested from: World Health Organization Department of Vaccines and Biologicals CH-1211 Geneva 27, Switzerland • Fax: + 41 22 791 4227 • £-mail: [email protected] • ©World Health Organization 2001 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. -
Results of Gal-Knockout Porcine Thymokidney Xenografts
Results of Gal-Knockout Porcine Thymokidney Xenografts The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Griesemer, A. D., A. Hirakata, A. Shimizu, S. Moran, A. Tena, H. Iwaki, Y. Ishikawa, et al. 2009. “Results of Gal-Knockout Porcine Thymokidney Xenografts.” American Journal of Transplantation 9 (12) (December): 2669–2678. doi:10.1111/j.1600-6143.2009.02849.x. Published Version doi:10.1111/j.1600-6143.2009.02849.x Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37364476 Terms of Use This article was downloaded from Harvard University’s DASH repository, WARNING: This file should NOT have been available for downloading from Harvard University’s DASH repository.;This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/ urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA NIH Public Access Author Manuscript Am J Transplant. Author manuscript; available in PMC 2010 November 20. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Am J Transplant. 2009 December ; 9(12): 2669±2678. doi:10.1111/j.1600-6143.2009.02849.x. Results of Gal-Knockout porcine thymokidney xenografts Adam D. Griesemer1, Atsushi Hirakata1, Akira Shimizu1, Shannon Moran1, Aseda Tena1, Hideyuki Iwaki1, Yoshinori Ishikawa1, Patrick Schule1, J. Scott Arn1, Simon C. Robson2, Jay A. Fishman3, Megan Sykes1, David H. Sachs1, and Kazuhiko Yamada1,4 1Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 2Transplant Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 3Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA. -
Hematopoietic Stem Cell Transplantation for 30 Patients with Primary Immunodeficiency Diseases: 20 Years Experience of a Single Team
Bone Marrow Transplantation (2006) 37, 469–477 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team Y Tsuji1, K Imai1,2, M Kajiwara1,3, Y Aoki1, T Isoda1, D Tomizawa1, M Imai1, S Ito1, H Maeda1, Y Minegishi1, H Ohkawa1, JYata 1, N Sasaki4, K Kogawa2, M Nagasawa1, T Morio1, S Nonoyama2 and S Mizutani1 1Department of Pediatrics and Developmental Biology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; 2Department of Pediatrics, National Defense Medical College, Saitama, Japan; 3Department of Blood Transfusion, University Hospital Faculty of Medicine, Tokyo Medical and Dental University, Tokyo, Japan and 4Department of Pediatrics, Saitama Medical School, Saitama, Japan We retrospectively analyzed our results of 30 patients with Introduction three distinctive primary immunodeficiency diseases (PIDs) – severe combined immunodeficiency (SCID, n ¼ 11), Primary immunodeficiency diseases (PIDs) are often Wiskott–Aldrich syndrome (WAS, n ¼ 11) and X-linked accompanied with life-threatening infections. Hematopoie- hyper-immunoglobulin M (IgM) syndrome (XHIM, n ¼ 8) tic SCT (HSCT) can be a treatment of choice to cure most – who underwent hematopoietic SCT (HSCT) during the of the lethal forms of immunodeficiencies, including severe past 20 years. Until 1995, all donors were HLA- combined immunodeficiency (SCID), Wiskott–Aldrich haploidentical relatives with T-cell depletion (TCD) syndrome (WAS) and X-linked hyper immunoglobulin M (n ¼ 8). Since 1996, the donors have been HLA-matched (IgM) syndrome (XHIM). An HLA-matched related donor related donors (MRD) (n ¼ 8), unrelated BM (UR-BM) (MRD), the best hematopoietic stem cell source, may not (n ¼ 7) and unrelated cord blood (UR-CB) (n ¼ 7). -
Selected Abstracts from the 12 Annual
Journal of Clinical Immunology (2021) 41 (Suppl 1):S1–S135 https://doi.org/10.1007/s10875-021-01001-x ABSTRACTS Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference Published online: 6 April 2021 # Springer Science+Business Media, LLC, part of Springer Nature 2021 Virtual, April 14-17 The study samples were cleared cryo-poor plasma. A chromatographic process using a new cation-exchange (CEX) resin that binds with high Sponsorship: Publication of this supplement was funded by the capacity to IgG and removes procoagulant activities was added in a se- Clinical Immunology Society. All content was reviewed and approved quential step to the standard removal/inactivation process. Testing of the by the Program Committee, which held full responsibility for the samples was performed using the standard process alone and then with abstract selections. sequential addition of the new CEX process. Procoagulant activity was tested using several standard methods, including, thrombin generation All contributors have provided original material assay, chromogenic FXIa assay, non-activated partial thromboplastin as submitted for publication in the Journal time (NaPTT), and FXI/FXIa ELISA. We further spiked our samples with of Clinical Immunology. additional coagulation factor XIa, in amounts exceeding any variability that may be caused due to sample differences, and tested these samples 01 Oral Presentations for procoagulant activity using the same methods. The procoagulant activities were reduced to low levels as determined by the thrombin generation assay: < 1.56 mIU/mL, chromogenic FXIa assay: < 0.16 mIU/mL, NaPTT: >250 s, FXI/FXIa ELISA: < 0.31 ng/mL. -
T-Cell Reconstitution After Thymus Xenotransplantation Induces Hair Depigmentation and Loss Anna L
ORIGINAL ARTICLE T-Cell Reconstitution after Thymus Xenotransplantation Induces Hair Depigmentation and Loss Anna L. Furmanski1, Ryan F.L. O’Shaughnessy1, Jose Ignacio Saldana1, Michael P. Blundell2, Adrian J. Thrasher2,NeilJ.Sebire3,E.GrahamDavies2,4 and Tessa Crompton1 Here we present a mouse model for T-cell targeting of hair follicles, linking the pathogenesis of alopecia to that of depigmentation disorders. Clinically, thymus transplantation has been successfully used to treat T-cell immunodeficiency in congenital athymia, but is associated with autoimmunity. We established a mouse model of thymus transplantation by subcutaneously implanting human thymus tissue into athymic C57BL/6 nude mice. These xenografts supported mouse T-cell development. Surprisingly, we did not detect multiorgan autoimmune disease. However, in all transplanted mice, we noted a striking depigmentation and loss of hair follicles. Transfer of T cells from transplanted nudes to syngeneic black-coated RAG À / À recipients caused progressive, persistent coat-hair whitening, which preceded patchy hair loss in depigmented areas. Further transfer experiments revealed that these phenomena could be induced by CD4 þ T cells alone. Immunofluorescent analysis suggested that Trp2 þ melanocyte-lineage cells were decreased in depigmented hair follicles, and pathogenic T cells upregulated activation markers when exposed to C57BL/6 melanocytes in vitro, suggesting that these T cells are not tolerant to self-melanocyte antigens. Our data raise interesting questions about the mechanisms underlying tissue-specific tolerance to skin antigens. Journal of Investigative Dermatology (2013) 133, 1221–1230; doi:10.1038/jid.2012.492; published online 10 January 2013 INTRODUCTION et al., 2007). Autoimmune vitiligo in humans typically Alopecia is a disfiguring form of hair loss, which may be presents as patchy skin depigmentation resulting from a reversible, or irreversible, as in scarring alopecias.